Pembrolizumab immune checkpoint inhibition
systematic review meta-analysis network meta-analysis
 

MK-3475 - Keytruda - lambrolizumab      

Select             pdf
Filter

  • Group by...
Trial Studied trt Control trt patientstagsROB Trial resultprogression or death (progression free survival PFS) death (overall survival)

gastric or gastro-oesophageal junction cancer (advanced)  

KEYNOTE-059 single-arm      NCTpembrolizumabnil -
Keynote 061, 2018    NCTpembrolizumabpaclitaxel2L 2nd line PD-L1 positive Risk of bias negative 27%-18%

Head and neck cancer  

KEYNOTE-040    NCTpembrolizumabstandard treatment2L 2nd line Risk of bias suggesting-19%

lung cancer (metastatic)  

Keynote 010 10mg, 2015      NCTpembrolizumab 10mgdocetaxel2L, PD-L1 positive 2nd+ line Risk of bias suggesting-21%-39%
Keynote 010 2mg, 2015      NCTpembrolizumab 2mgdocetaxel2L, PD-L1 positive 2nd+ line Risk of bias suggesting-12%-29%
Keynote 042 (>=1%), 2018    NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias suggesting-19%
Keynote 024, 2015      NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias suggesting-50%-40%
Keynote 042 (>=50%), 2018    NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias suggesting-31%
Keynote 042 (>=20%), 2018    NCTpembrolizumabplatinum-based CT1L, PDL1 positive 1st line PD-L1 positive Risk of bias suggesting-23%
KEYNOTE-021 phase 2, 2016      NCTpembrolizumab + platinum-based CTplatinum-based CT1L nonsquamous 1st line nonsquamous NSCLC Exploratory suggesting-47%-46%
Keynote 189, 2018      NCTpembrolizumab + platinum-based CTplatinum-based CT1L PD-L1 positive nonsquamous 1st line nonsquamous NSCLC Low risk of bias conclusive-48%-51%
Keynote 407, 2018      NCTpembrolizumanb + CTplatinum-based CT1L squamous squamous NSCLC Risk of bias suggesting-36%

melanoma  

KEYNOTE 002 (10mg/kg Q3W), 2015      NCTpembrolizumab 10mg/kgchemotherapy2L 2nd line Exploratory suggesting-50%
KEYNOTE 002 (2mg/kg Q3W), 2015      NCTpembrolizumab 2mg/kgchemotherapy2L 2nd line Exploratory suggesting -43%
KEYNOTE-006 (every 2W), 2015      NCTpembrolizumab (every 2W)ipilimumab1L 1st line Risk of bias suggesting -42%-32%
KEYNOTE-006 (every 3W), 2015      NCTpembrolizumab (every 3W)ipilimumab1L 1st line Risk of bias suggesting -42%-32%
KEYNOTE-001, 2014      NCTpembrolizumab 2mg/kgpembrolizumab 10mg/kg2L 2nd line Exploratory negative-16%9%
KEYNOTE-054, 2018      NCTpembrolizumabplaceboadjuvant adjuvant Low risk of bias conclusive -43%

multiple myeloma  

KEYNOTE-185, 2018    NCTpembrolizumab, lenalidomide, dexametahsonelenalidomide, dexamethasonenot eligible for ASCTRisk of bias remark
KEYNOTE-183, 2018    NCTpembrolizumab + pomadoline + dexamethasonepomadoline + dexamethasonerrMMRisk of bias negative

urothelial carcinoma (advanced)  

KEYNOTE-052, 2017 single-arm      NCTpembrolizumab 1st line Risk of bias -
KEYNOTE-045, 2017    NCTpembrolizumabchemotherapy2nd line 2nd line Risk of bias suggesting-2%-27%
Keynote 361 monotherapy    NCTpembrolizumabchemotherapyfirst lineremark



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons